Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 8/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 3/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1588118 | 0.86 | DGAT1 (0.43) | DGAT1KDM4EACACBNAMPTACACA | |
| SCHEMBL1588120 | 0.86 | DGAT1 (0.43) | DGAT1KDM4EACACBNAMPTACACA | |
| SCHEMBL1588545 | 0.86 | DGAT1 (0.43) | DGAT1KDM4EACACBNAMPTACACA | |
| SCHEMBL15152756 | 0.85 | DGAT1 (0.47) | GPR119DGAT1NAMPT | |
| SCHEMBL5532726 | 0.85 | DGAT1 (0.60) | GPR119DGAT1ACACBNAMPTHRH3 | |
| SCHEMBL15152753 | 0.85 | DGAT1 (0.47) | GPR119DGAT1NAMPT | |
| SCHEMBL13769570 | 0.85 | DGAT1 (0.60) | GPR119DGAT1ACACBNAMPTHRH3 | |
| SCHEMBL602562 | 0.84 | MAPT (0.48) | GPR119DGAT1 | |
| SCHEMBL602561 | 0.84 | MAPT (0.48) | GPR119DGAT1 | |
| SCHEMBL1589689 | 0.84 | DGAT1 (0.48) | DGAT1POLBACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092547-A1 | CHEMICAL COMPOUNDS 979 | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092547-A1 | CHEMICAL COMPOUNDS 979 | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092547-A1 | CHEMICAL COMPOUNDS 979 | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-2190840-A2 | CHEMICAL COMPOUNDS 979 | AstraZeneca AB (SE) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009024821-A2 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024821-A2 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092547-A1 | CHEMICAL COMPOUNDS 979 | DGAT1, DGAT2, ACAT2 | GPR119 533/4885DGAT1 1/4885KDM4E 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.